Abstract
Lisdexamfetamine (LDX) is the only available stimulant prodrug formulation that has been approved by the Food and Drug Administration (FDA) for treatment of ADHD in children and adults. It is enzymatically hydrolyzed to the active d-amphetamine and essential amino acid L-lysine. This rate limited enzyme mediated step underlies the consistent, predictable levels throughout the day and limits its potential for misuse. It is effective, safe and well tolerated and has an adverse effect profile comparable to other extended release stimulant formulations. The d-amphetamine levels from LDX are more consistent than that from extended release mixed amphetamine salts. LDX has shown efficacy for ADHD in clinical trials involving children and adults. Ongoing research studies are attempting to establish its long term efficacy and tolerability in patients with ADHD and also its use for some novel applications in patients with depression and other psychiatric disorders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
